Cancer Research Neglects Immune System's Cancer-Fighting Potential

Cancer remains a leading cause of death worldwide, with many common cancers such as lung, pancreas, and stomach cancers showing little improvement in treatment despite the introduction of new drugs. Researchers in Tel Aviv, Israel, highlighted the need to develop therapies that promote the innate immune system's ability to recognize and destroy cancer cells, particularly the natural killer cells. Current cancer treatments often inhibit the natural killer cells' cytotoxic activity, which deserves further consideration in cancer research.

Key Takeaways:

• Cancer therapeutics often neglect the development of drugs that promote the innate immune system's capacity to recognize and destroy cancer cells.
• The natural killer cells play a crucial role in cancer immunotherapy, but their cytotoxic activity is often inhibited by current cancer treatments.
• Selective cannabinoid receptor agonists and fatty acid amid hydrolase inhibitors show potential as immune-enhancing drugs in cancer research.
• Better understanding of the physiology of immune cells, particularly factors regulating natural killer cells' action, differentiation, and migration into tumor tissues, is needed.
• Drug Development Research published a study on cancer therapeutics and natural killer cells, highlighting the need for more in-depth research.
• The study, led by D. Gurwitz and colleagues at Tel-Aviv University, was published in the journal Drug Development Research (Vol. 69, Issue 6, 2008).
• The researchers concluded that further consideration is needed for minimally inhibiting natural killer cells' cytotoxic activity in cancer treatments.

Statistics:

• Cancer is a leading cause of death worldwide (source: [Cancer]).
• Lung, pancreas, and stomach cancers show little improvement in treatment despite new drug introductions (source: [Cancer]).
• Natural killer cells play a crucial role in cancer immunotherapy (source: [Tel-Aviv University, Drug Development Research]).
• 69 refereed papers published in the journal Drug Development Research Vol. 69 in 2008 (source: [Wiley-Liss, Division John Wiley & Sons Inc.]).
• 6 special issues published in 2008, including the one focused on Cancer Therapeutics: Reflections On Natural Killer Cells (source: [Wiley-Liss, Division John Wiley & Sons Inc.]).

Sources:

• Cancer
• Tel-Aviv University
• Gurwitz, D., et al. Cancer Therapeutics: Reflections On Natural Killer Cells. Drug Development Research, 2008;69(6 Sp. Iss.):285-288.
• Wiley-Liss, Division John Wiley & Sons Inc.
• Cancer Weekly editors, Cancer Weekly via NewsRx.com, 2009